Description:

Ticagrelor 90mg Tablets  (branded as Timinta 90) is an antiplatelet medication (blood thinner) that prevents platelets from sticking together and forming harmful blood clots. It is used to reduce the risk of heart attack, stroke, or cardiovascular death in patients with acute coronary syndrome (ACS), unstable angina, or a history of heart attack, often in combination with low-dose aspirin.

Prescription:

• Yes

Therapeutic Category:

• Antiplatelet Agent / P2Y12 Receptor Inhibitor

Active Ingredients/Composition:

• Ticagrelor IP 90 mg per tablet

Variant:

• Standard 90 mg film-coated tablets (also available as Timinta 60 mg in the same brand line; common pack is 10x1x14 tablets blister)

Consume Type:

• Oral

Directions/Usage:

• Take with or without food. Typical adult dosage (for ACS or post-heart attack): Loading dose of 180 mg (two 90 mg tablets) initially, followed by 90 mg twice daily (approximately 12 hours apart). Usually combined with low-dose aspirin (75-100 mg once daily). Continue for up to 12 months or as prescribed (longer in some cases for chronic use at 60 mg twice daily after initial period). Swallow whole; do not crush or chew. Follow doctor’s exact instructions; do not stop abruptly without medical advice.

Common Side Effects:

• Bleeding (e.g., bruising easily, nosebleeds, prolonged bleeding from cuts, heavier periods), shortness of breath (dyspnea), dizziness, headache, nausea, fatigue, elevated uric acid levels (risk of gout), or mild gastrointestinal upset. Serious (rare): major bleeding, intracranial hemorrhage, or allergic reactions.

Package Type:

• Blister pack of 10x1x14 tablets (140 tablets total; strip of 14 tablets common)

Storage Advice:

• Store in a cool, dry place below 25-30°C, protected from light and moisture. Keep in original packaging. Keep out of reach of children.

Safety Advice:

• Prescription only; requires medical supervision. High risk of serious (sometimes fatal) bleeding—avoid if active bleeding, history of intracranial hemorrhage, or recent major surgery. Do not use with strong CYP3A4 inhibitors/inducers without adjustment. Caution in severe liver impairment, history of bleeding disorders, or planned surgery (may need to stop 5 days prior). Monitor for bleeding signs; report unusual bruising, black stools, blood in urine, or severe headache immediately. Avoid abrupt discontinuation (increased clot risk). Consult doctor if pregnant, breastfeeding, or on other blood thinners. Often used with aspirin—do not add extra aspirin without advice.

Product Substitutes:

• Brilinta 90 mg Tablets (AstraZeneca, original brand)
• Ticagat 90 mg or other generics (e.g., Ticagrelor by Sun Pharma, Cipla, or Hetero)
• Tigatrust 90 mg
• Other ticagrelor 90 mg generics in India/Ghana markets

Manufacturer/Marketer:

• Johnlee Pharmaceuticals Pvt. Ltd.

Country of Origin:

• India